ACLX Quote, Financials, Valuation and Earnings

Agios Pharmaceuticals has a net margin of -99.37% compared to Arcellx's net margin of -1115.71%. Arcellx's return on equity of -9.11% beat Agios Pharmaceuticals's return on equity of 71.3%.

Arcellx has a consensus price target of $116.38, signalling upside risk potential of 80.01%. On the other hand Agios Pharmaceuticals has an analysts' consensus of $57.00 which suggests that it could grow by 71.07%. Given that Arcellx has higher upside potential than Agios Pharmaceuticals, analysts believe Arcellx is more attractive than Agios Pharmaceuticals.

Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Agios Pharmaceuticals has a beta of 0.874, suggesting its less volatile than the S&P 500 by 12.615%.

Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agios Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx pays -- of its earnings as a dividend. Agios Pharmaceuticals pays out -- of its earnings as a dividend.

Arcellx quarterly revenues are $26M, which are larger than Agios Pharmaceuticals quarterly revenues of $9M. Arcellx's net income of -$25.9M is lower than Agios Pharmaceuticals's net income of $947.9M. Notably, Arcellx's price-to-earnings ratio is -- while Agios Pharmaceuticals's PE ratio is 2.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 21.68x versus 57.66x for Agios Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Catalyst Pharmaceuticals has a net margin of -99.37% compared to Arcellx's net margin of 34.1%. Arcellx's return on equity of -9.11% beat Catalyst Pharmaceuticals's return on equity of 27.81%.

Arcellx has a consensus price target of $116.38, signalling upside risk potential of 80.01%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $33.00 which suggests that it could grow by 48.58%. Given that Arcellx has higher upside potential than Catalyst Pharmaceuticals, analysts believe Arcellx is more attractive than Catalyst Pharmaceuticals.

Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.787, suggesting its less volatile than the S&P 500 by 21.251%.

Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

Arcellx quarterly revenues are $26M, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $128.7M. Arcellx's net income of -$25.9M is lower than Catalyst Pharmaceuticals's net income of $43.9M. Notably, Arcellx's price-to-earnings ratio is -- while Catalyst Pharmaceuticals's PE ratio is 18.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 21.68x versus 5.88x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences has a net margin of -99.37% compared to Arcellx's net margin of 16.61%. Arcellx's return on equity of -9.11% beat Gilead Sciences's return on equity of 0.64%.

Arcellx has a consensus price target of $116.38, signalling upside risk potential of 80.01%. On the other hand Gilead Sciences has an analysts' consensus of $99.96 which suggests that it could grow by 11.14%. Given that Arcellx has higher upside potential than Gilead Sciences, analysts believe Arcellx is more attractive than Gilead Sciences.

Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.179, suggesting its less volatile than the S&P 500 by 82.12%.

Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 3.43% to investors and pays a quarterly dividend of $0.77 per share. Arcellx pays -- of its earnings as a dividend. Gilead Sciences pays out 67.24% of its earnings as a dividend. Gilead Sciences's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Arcellx quarterly revenues are $26M, which are smaller than Gilead Sciences quarterly revenues of $7.5B. Arcellx's net income of -$25.9M is lower than Gilead Sciences's net income of $1.3B. Notably, Arcellx's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 999.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 21.68x versus 3.98x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -99.37% compared to Arcellx's net margin of --. Arcellx's return on equity of -9.11% beat Viking Therapeutics's return on equity of --.

Arcellx has a consensus price target of $116.38, signalling upside risk potential of 80.01%. On the other hand Viking Therapeutics has an analysts' consensus of $110.00 which suggests that it could grow by 182.92%. Given that Viking Therapeutics has higher upside potential than Arcellx, analysts believe Viking Therapeutics is more attractive than Arcellx.

Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.344%.

Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Arcellx quarterly revenues are $26M, which are larger than Viking Therapeutics quarterly revenues of --. Arcellx's net income of -$25.9M is lower than Viking Therapeutics's net income of -$24.9M. Notably, Arcellx's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 21.68x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.